AstiVita Limited (AIR) announced new product launch ­ DrZinX Mouth It advised that its first production with its invention including Hinokitiol will be completed in early July 2021 and should be ready for sale through AMAZON EU by the end of July. AIR has filed a joint patent application with ANO on a 50/50 basis, for a new sanitising antimictobial hand, face and body moisturiser product with SPF15 which includes a percentage of zinc and hinokitiol as part of the patented invention. The AIR Board makes no claims that this product will cure Covid-19 or in fact will stop contracting Covid-19. Like prior invention, the product has been sent to MSL Solution Providers in London to test for its effectiveness. To test the efficacy of product, plan to conduct a test against the feline coronavirus to the EN Standard 14476:2013+A2:2019. Feline coronavirus is the globally accepted surrogate for COVID-19. Do not expect these results to be available for some weeks Further, there will be no impact to revenue for fiscal year 2020 and cannot predict what impact if any for fiscal year 2021. Whilst the main ingredients, zinc and hinokitiol, in the invention are well known, the science behind the invention and the use of these ingredients in products is complex. It is beyond the scope of this announcement to explain the detail of such science which of itself is not market sensitive information nor necessarily informative for disclosure purposes. However, for those investors who have an interest in such details a copy of the full patent is for ease of reference (in addition to being publicly available). What is important and valuable is whether the assessors of the patent agree that the science set out in patent is sufficiently novel that it can be granted patent protection. Whilst AIR is confident its invention is novel and patenable, there can be no assurance that the patent application will be granted. The product supplied to MSL Solution Providers in the UK for testing is a genuine sanitiser hand, face and body moisturiser using a percentage of invention, the subject of the patent application. A standard organism feline coronavirus test of the product will be completed in approximately 5 weeks by MSL, at which stage AIR will confirm if the testing was successful. MSL will conduct a standard test, the non-standard refers to the organism used in the test, being an organism grown in the lab (Munich strain) and in respect of which there is no other comparable organism (hence it being "non-standard"). The standard method BS EN 14476 describes a test method and the minimum requirements for virucidal activity of a chemical disinfectant and antiseptic products that form a homogenous physically stable preparation when diluted with hard water - or in the case of ready to use products that are not diluted when applied, - with water. Products can only be tested at a concentration of 80% (97% with a modified method for special cases) as some dilution is always produced by adding the test organisms and interfering substances. This European Standard applies to products that are used in the medical area in the fields of hygienic handrub, hygienic handwash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding or other means and textile disinfection." The proposed application of the invention is a sanitising hand, face and bodymoisturiser similar to other antiseptic products on the market advertising their antiseptic capabilities.